Suggest a Low-Molecular-Weight Heparin for Cancer-Associated VTE

September 2017

We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.

The role of DOACs (Eliquis, Xarelto, etc) is expanding. Chest guidelines now favour these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.

But don't recommend jumping to a DOAC first-line to treat or prevent recurrent VTE in patients with cancer. There's limited evidence about the efficacy and safety of DOACs in this case.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Influenza Help Patients Choose a Flu Vaccine for 2017/18 Season
Liver Disease Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease
Dermatology Tell Patients to Think of New Tattoos as Wounds
Neurology & Pain Consider Pros and Cons of Meds for Diabetic Peripheral Neuropathy
Hypertension Watch for Commonly Used Meds and Supplements That May Increase Blood Pressure
IBS Make Sure Patients With Heavy Alcohol Use Don't Use Viberzi
Cannabinoids Explain Risks and Benefits of Medical Marijuana
Multiple Sclerosis Reduce Side Effects of Multiple Sclerosis Meds
Storage & Disposal Don't Break the Cold Chain With Refrigerated and Frozen Meds
Women's Health Point Out Differences in Prenatal Vitamins to Pregnant Women
Anticoagulants Suggest a Low-Molecular-Weight Heparin for Cancer-Associated VTE
Dosage Forms Be Ready to Answer Questions About Chewable Tabs

Suggest a Low-Molecular-Weight Heparin for Cancer-Associated VTE

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents